Business Description

CohBar is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar’s founders of a novel group of naturally occurring, mitochondrial peptides encoded in the mitochondrial genome, which regulate metabolism, cell death and other important biological functions, and whose activity declines with age. CohBar’s efforts focus on the development of these peptides into novel therapeutics that offer the potential to address a broad range of large population and orphan diseases. The company and its founders have discovered more than 100 mitochondrial-derived peptides which may be developed into breakthrough treatments for a number of these diseases with enormous unmet medical needs.

Click Here to View Latest Profile

Latest Presentation

Contact Information

Investor Relations
Jordyn Tarazi
Director, Investor Relations
T: (650) 445-4441
jordyn.tarazi@cohbar.com

Company Contact
CohBar, Inc.
1455 Adams Drive
Suite 2050
Menlo Park, CA 94025
T: (650) 446-7888